Severe gastrointestinal bleeding due to erlotinib and celecoxib therapy: additional effect?

Severe gastrointestinal bleeding due to erlotinib and celecoxib therapy: additional effect?

Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related dead worldwide and accounts for over 85% of all lung cancers. Furthermore, the majority of patients with NSCLC present with advanced, metastatic disease at the time of diagnosis. For most patients with non-small cell lung canc...

Full description

Bibliographic Details
Main Authors: Maddalena Zippi, Angeloluca De Quarto, Chiara Marzano, Claudio Cassieri, Pietro Crispino, Giampiero Traversa, Giuseppe Occhigrossi, Paola Gnerre, David Terracina
Format: Article
Language:English
Published: PAGEPress Publications 2016-08-01
Series:Italian Journal of Medicine
Subjects:
Epidermal growth factor receptor
tyrosine kinase inhibitors
erlotinib
gastrointestinal bleeding
non-small cell lung cancer
celecoxib.
Online Access:http://www.italjmed.org/index.php/ijm/article/view/689

Internet

http://www.italjmed.org/index.php/ijm/article/view/689

Similar Items